Trial Profile
A Single-arm Phase II Study of Chemoradiotherapy Plus Pembrolizumab as Adjuvant Therapy for Locally Advanced Esophageal Squamous Cell Carcinoma Patients at High Risk of Recurrence Following Preoperative Chemoradiotherapy Plus Surgery
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 26 Feb 2024
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary) ; Cisplatin
- Indications Oesophageal cancer; Squamous cell cancer
- Focus Therapeutic Use
- 20 Jan 2024 Results assessing safety and efficacy of adjuvant chemoradiotherapy plus pembrolizumab for locally advanced esophageal squamous cell carcinoma with high risk of recurrence after neoadjuvant CRT plus surgery presented at the 2024 Gastrointestinal Cancers Symposium.
- 05 Jun 2022 Planned number of patients changed from 46 to 26.
- 05 Jun 2022 Planned End Date changed from 1 Jan 2025 to 30 Jun 2025.